Tricuspid Version of Abbott’s MitraClip Improves Short-Term Outcomes In TRILUMINATE
Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.
